Search

Take a look back at some of the biggest cancer science stories from this past year.

… Monday, December 21, 2020 Summary Many advances in cancer care come from applying the insights of basic science. This past year, Memorial Sloan Kettering scientists made fundamental discoveries that have direct relevance to cancer treatment. Below are ten of our favorites. 1. Good news for people with

A team of experts at Memorial Sloan Kettering shared their insights on prostate cancer and men’s health in an Information Session for patients, caregivers and those at increased risk for the disease.

… Thursday, October 15, 2020 A team of experts at Memorial Sloan Kettering shared their insights on prostate cancer and men’s health in an Information Session for patients, caregivers and those at increased risk for the disease.   Members of the MSK community joined the session to have their most pressing

The largest study of its kind to look at data from children with cancer finds inherited cancer genes are more common than expected.

… Monday, February 15, 2021 Summary Experts in pediatric cancer genetics have found that inherited cancer genes are more common than expected in children with cancer. Because cancers in children are rare, many details about their biology remain unknown. In the field of cancer genetics, there’s a limited

Experience the words and artwork of three patients who found hope and healing through MSK art programs.

… Thursday, January 24, 2019 Summary Three patients share how MSK’s art-making programs helped them express their emotions and heal during their cancer treatment. Making art can be a powerful form of therapy. It can be especially beneficial for people with cancer, helping them to cope better with physical

… Monday, October 6, 2025 Memorial Sloan Kettering Cancer Center (MSK) today announced the following awards and appointments: Maria Jasin Awarded the 2025 Peral Meister Greengard Prize Maria Jasin Maria Jasin, PhD , developmental biologist and William E. Snee Chair, has been  selected as the 2025 recipient

The FDA has approved the targeted drug repotrectinib for patients 12 and older with tumors that carry gene changes called NTRK fusions. The trial that resulted in the approval was led by MSK investigators.

… Thursday, June 13, 2024 On June 13, 2024, a targeted drug called  repotrectinib (Augtyro TM ) received accelerated approval from the US Food and Drug Administration (FDA) for treating cancers caused by gene changes called  NTRK fusions. The clinical trial that resulted in the approval was led globally

A prostate-specific antigen (PSA) test taken for the first time between the ages of 44 and 50 can predict the likelihood that a man will die from prostate cancer over the next 25 to 30 years, according to researchers at Memorial Sloan Kettering Cancer Center.

… Thursday, May 19, 2011 A prostate-specific antigen (PSA) test taken for the first time between the ages of 44 and 50 can predict the likelihood that a man will die from prostate cancer over the next 25 to 30 years, according to researchers at Memorial Sloan Kettering Cancer Center. The findings, which

Pituitary adenomas continue to grow in a small subset of patients despite treatment with standard surgery and radiotherapy. Recognizing the significant unmet needs in this cohort, we recently published a review of the latest treatment options.

… Wednesday, October 14, 2020 Pituitary adenomas continue to grow in a small subset of patients despite treatment with standard surgery and radiotherapy. Further treatments may provide symptom relief but are rarely definitive for disease management in this cohort. Recognizing the significant unmet needs

Learn more about world-class cancer care on Long Island at MSK Nassau.

… Tuesday, March 26, 2019 Summary Memorial Sloan Kettering has opened MSK Nassau , expanding its cancer care in Nassau County. The Uniondale facility includes a number of features designed to make treatment easier and more convenient. Memorial Sloan Kettering has been caring for people on Long Island for

A new approach for treating melanoma combines the immunotherapy drug ipilimumab with chemotherapy that treats only the area affected by cancer.

… Friday, February 2, 2018 Summary MSK investigators are reporting on a new approach for treating melanoma in the arm or leg. The therapy combines the immunotherapy drug ipilimumab with chemotherapy for only the affected limb. For some people with cancer, drugs that help the immune system recognize and